The most studied molecular targets in breast cancer drug discovery included epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor‐2 (VEGFR‐2), cyclin‐dependent kinases (CDKs), tubulin, and hormone receptors (ERα and ERβ) (Table 4). This evidence concerns the gene KDR and breast carcinoma.